In this article, we will look at the 10 Best NYSE Stocks to Buy Under $20.
On August 9, Tom Lee, Fundstrat’s Managing Partner and Head of Research, appeared on CNBC’s ‘Closing Bell’ to talk about the markets. He stated that the market is consolidating and getting direction from what it does, as it did gain 28% from the April lows, and that needs to be digested.
The market is now in the dog days of August, where liquidity is low, and he feels that the market is holding its breath being in a period where the Fed is not going to make an interest rate decision till September.
READ ALSO: 10 Undervalued Defensive Stocks to Buy According to Analysts and 10 Most Undervalued Biotech Stocks to Buy Now.
Therefore, some of the key macro is on hold at the moment and the markets are “wait and see,” but the pullbacks have been shallow, according to him.
Lee added that there is a sober view about markets at the moment, with investors appearing cautious about valuations. Many have pointed to what they view as “mixed results for earnings.”
With these trends in view, let’s look at the best NYSE stocks to buy under $20.
A close-up view of a stock market floor, traders bustling around the trading board.
Our Methodology
We used stock screeners to make a list of NYSE stocks trading below $20 per share and selected the top 10 with the highest number of hedge fund holders as of Q1 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.
Note: All data was sourced on August 11.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Best NYSE Stocks to Buy Under $20
10. Ambev S.A. (NYSE:ABEV)
Stock Price: $2.24
Number of Hedge Fund Holders: 21
Ambev S.A. (NYSE:ABEV) is one of the best NYSE stocks to buy under $20. In a report released on August 1, Isabella Simonato from Bank of America Securities maintained a Hold rating on Ambev S.A. (NYSE:ABEV) without assigning a price target.
The rating update followed Ambev S.A.’s (NYSE:ABEV) fiscal Q2 2025 results on July 31, with net revenue (organic) growth of 3.4% and top-line performance driven by net revenue per hectoliter (NR/hl) growth of 8.4%.
Normalized EBITDA (organic) grew by 7.6% with all of the company’s reporting segments delivering EBITDA growth.
Management also reported that normalized profit for the quarter rose 15.2% to R$2.8327 billion compared to R$2.4591 billion in fiscal Q2 2024. This growth was attributed to lower income tax expenses and EBITDA growth, particularly offset by higher net financial results.
Ambev S.A. (NYSE:ABEV) produces, distributes, and sells beverages. Its offerings include carbonated soft drinks, beer, and other non-alcoholic and non-carbonated products.
The company’s operations are divided into the following geographical segments: Brazil, Central America and the Caribbean (CAC), and Canada.
9. Haleon plc (NYSE:HLN)
Stock Price: $9.54
Number of Hedge Fund Holders: 22
Haleon plc (NYSE:HLN) is one of the best NYSE stocks to buy under $20. In a report released on August 4, Morgan Stanley maintained a Buy rating on Haleon plc (NYSE:HLN) with a price target of $10.95.
Haleon plc (NYSE:HLN) reported unaudited results for H1 2025 on June 30, reporting notable growth in EMEA & LatAm and Asia-Pacific, while showing continued outperformance in Oral Health.
Management reported organic revenue growth across EMEA & LatAm (+5.2%) and Asia-Pacific (+5.0%), partially offsetting a 0.4% decline in North America. The trends reflected a weak US consumer and retail environment.
The company also reported that 58% of businesses gained or maintained market share, suggesting the resilience of its brand portfolio. Free cash flow for the first half of the year reached £734 million, up £184 million year-on-year, primarily due to progress on working capital initiatives.
Haleon plc (NYSE:HLN) provides personal healthcare products, with a focus on consumer healthcare. The company’s operations are divided into the following geographical segments: North America, EMEA and LatAm, and Asia Pacific.
